Design, Synthesis and Anticancer Activity of 4-Morpholinothieno[3,2-D]-Pyrimidine Derivatives Bearing Chromone Moiety

Abstract:

A series of 4-morpholinothieno [3,2-d] pyrimidine derivatives containing chromone moiety (5a-5e) were synthesized and their structures were confirmed by ¹H NMR and MS spectrum. The synthesized compounds were evaluated for their cytotoxicity against three cancer cell lines (PC-3, H460, SGC-7901). Two of them exhibited moderate cytotoxicity and high-selectivity against one or more cell lines. At 10μM levels, the inhibition rate of compound 5c against SGC-7901 cell lines was 58.9%, and that of compound 5d against PC-3 cell lines was 56.4%.

• Periodical: Advanced Materials Research (Volumes 989-994)
• Pages: 568-571
• DOI: https://doi.org/10.4028/www.scientific.net/AMR.989-994.568
• Online since: July 2014
• Authors: Cheng Yu Sun, Chen Chen, Chun Jiang Wu, Peng Wu Zheng*, Wu Fu Zhu
• Keywords: 4-Morpholinothieno [3,2-D] Pyrimidine, Anticancer Activity, Chromone, PI3K/mTOR Inhibitors

References

[1] Heron M. Leading causes for 2006. National Vital Statistics Reports, 2010, 58 (14): 1-100.

[2] Rodon J, Dienstmann R, Serra V, et al. Development of PI3K inhibitors: lessons learned from early clinical trials. Nature Reviews Clinical Oncology, 2013, 10(3): 143-153.

DOI: 10.1038/nrclinonc.2013.10

[3] Vanhaesebroeck B, Stephens L, Hawkins P. PI3K signalling: the path to discovery and understanding. Nature Reviews Molecular Cell Biology, 2012, 13(3): 195-203.

DOI: 10.1038/nrm3290

[4] Folkes AJ, Ahmadi K, Alderton W. K, et al. The identification of 2-(1H-indazol-4-yl)-6-(4-methanesulfonyl-piperazin-1-ylmethyl)-4-morpholin-4-yl-thieno[3, 2-d] pyrimidine (GDC-0941) as a potent, selective, orally bioavailable inhibitor of class I PI3 kinase for the treatment of cancer. J. Med. Chem., 2008, 51(18): 5522-5532.

DOI: 10.1021/jm800295d

[5] Heffron TP, Berry M, Castanedo G, et al. Identification of GNE-477, a potent and efficacious dual PI3K/ mTOR inhibitor. Bioorg. Med. Chem. Lett., 2010, 20(8): 2408–2411.

DOI: 10.1002/chin.201040171

[6] Daniel P, Sampath D, Berry M, et al. Discovery of (thienopyrimidin-2-yl) aminopyrimidines as potent, selective, and orally available pan-PI3-kinase and dual pan-PI3-kinase/mTOR inhibitors for the treatment of cancer. J. Med. Chem., 2010, 53(3): 1086–1097.

DOI: 10.2210/pdb3l17/pdb

[7] Junttila T. T., Akita R. W., Parsons K, et al. Ligand-Independent HER2/HER3/PI3K Complex Is Disrupted by Trastuzumab and Is Effectively Inhibited by the PI3K Inhibitor GDC-0941. Cancer Cell, 15, 429–440 (2009).

DOI: 10.1016/j.ccr.2009.03.020

[8] Wu Fu Zhu, Xin Zhai, Sai Li, et al. Synthesis and cytotoxic activity of novel 2, 6-disubstituted-4-morpholinothieno[3, 2-d]pyrimidines as potent anti-tumor agents. Chin. Chem. Lett., 2012, 23(6): 703-706.

DOI: 10.1016/j.cclet.2012.04.012

[9] Wufu Zhu, Xin Zhai, Qiangqiang Fu, et al. Design, synthesis and anticancer activity of 4-morpholinothieno[3, 2-d]pyrimidine derivatives bearing arylmethylene hydrazine moiety. Chem. Pharm. Bull., 2012, 60(8): 1037-1045.

DOI: 10.1248/cpb.c12-00342

[10] Q. -D. Tu, D. Li, Y., et al. Design and Syntheses of novel N'-(4-Oxo-4H-Chromen-3-Yl)Methylene)Benzohydr-azide as Inhibitors of cyanobacterial Fructose-1, 6-/Sedoheptulose-1, 7-Bisphosphatase. Bioorg. Med. Chem., 2013, 21 (11): 2826-2831.

DOI: 10.1016/j.bmc.2013.04.003